Trends in immunotherapy of fungal infections

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 1, 1997, Pages 51-55

  Kullberg, B J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 1; TUMOR NECROSIS FACTOR;

ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CONFERENCE PAPER; CRYPTOCOCCUS NEOFORMANS; HOST RESISTANCE; IMMUNOTHERAPY; MYCOSIS; PRIORITY JOURNAL;

CYTOKINES; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; MYCOSES;

EID: 0031051912     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575121     Document Type: Conference Paper

References (31)

1. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. Journal of Infectious Diseases 1991, 163: 1177-1184.
2. Steinshamn S, Waage A: Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infection and Immunity 1992, 60: 4003-4008.
3. Netea MG, Blok WL, Kullberg BJ, Bemelmans M, Vogels MTE, Buurman WA, Van der Meer JWM: Pharmacological inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. Journal of Infectious Diseases 1995, 171: 393-399.
4. Louie A, Baltch AL, Smith RP, Franke MA, Ritz WJ, Singh JK, Gordon MA: Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infection and Immunity 1994, 62: 2761-2772.
5. Kullberg BJ, Van 't Wout JW: Cytokines in the treatment of fungal infections. Biotherapy 1994, 7: 195-210.
6. Djeu JY, Blanchard DK, Halkias D, Friedman H: Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-g and tumor necrosis factor. Journal of Immunology 1986, 137: 2980-2984.
7. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infection and Immunity 1993, 61: 1185-1193.
8. Kullberg BJ, Van 't Wout JW, Hoogstraten C, Van Furth R: Recombinant interferon-g enhances resistance to acute disseminated Candida albicans infection in mice. Journal of Infectious Diseases 1993, 168: 436-443.
9. Joly V, Saint-Julien L, Carbon C, Yeni P: In vivo activity of interferon-g in combination with amphotericin B in the treatment of experimental cryptococcosis. Journal of Infectious Diseases 1994, 170: 1331-1334.
10. Gallin JI, Malech HL, Melnick DA, and the International Chronic Granulomatous Disease Cooperative Study Group: A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 1991, 324: 509-516.
11. Rex JH, Bennett JE, Gallin JI, Malech HL, Decarlo ES, Melnick DA: In vivo interferon-g therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. Journal of Infectious Diseases 1991, 163: 849-852.
12. Nemunaitis J, Appelbaum FR, Lilleby K, Buhles WC, Rosenfeld C, Zeigler ZR, Shadduck RK, Singer JW, Meyer W, Buckner CD: Phase I study of recombinant interleukin-1b in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 1994, 83: 3473-3479.
13. Weisdorf D, Katsanis E, Verfaillie C, Ramsay NKC, Haake R, Garrison L, Blazar BR: Interleukin-1 a administered after autologous transplantation: a phase I/II clinical trial. Blood 1994, 84: 2044-2049.
14. Van 't Wout JW, Van der Meer JWM, Barza M, Dinarello CA: Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin- 1. European Journal of Immunology 1988, 18: 1143-1146.
15. Kullberg BJ, Van 't Wout JW, Van Furth R: Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infection and Immunity 1990, 58: 3319-3324.
16. Vogels MTE, Van der Meer JWM: Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrobial Agents and Chemotherapy 1992, 36: 1-5.
17. Vogels MTE, Mensink EJBM, Ye K, Boerman OC, Verschuren CMM, Dinarello CA, Van der Meer JWM: Differential gene expression for IL-1 receptor antagonist, IL-1, and TNF receptors and IL-1 and TNF synthesis may explain IL-1-induced resistance to infection. Journal of Immunology 1994, 153: 5772-5780.
18. Clemons KV, Brummer E, Stevens DA: Cytokine treatment in central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrobial Agents and Chemotherapy 1994, 38: 460-464.
19. Romani L, Puccetti P, Mencacci A, Cenci E, Spaccapelo R, Tonnetti L, Grohmann I, Bistoni F: Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. Journal of Immunology 1994, 152: 3514-3521.
20. Romani L, Mencacci A, Grohmann U, Mocci S, Mosci P, Puccetti P, Bistoni F: Neutralizing antibody to interleukin-4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis. Journal of Experimental Medicine 1992, 176: 19-25.
21. Puccetti P, Mencacci A, Cenci E, Spaccapelo R, Mosci P, Enssle KH, Romani L, Bistoni F: Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. Journal of Infectious Diseases 1994, 169: 1325-1331.
22. Herbrecht R, Cordonnier C: Impact of cytokines and growth factors in the antifungal armamentarium. In: Meunier F (ed) Ballière's clinical infectious diseases. Ballière Tindall, London, 1995, p. 141-155.
23. Karbassi A, Backer JM, Foster JS, Moore RN: Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: evidence for augmented expression of mannose receptors. Journal of Immunology 1987, 139: 417-421.
24. Brummer E, Stevens DA: Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing. Journal of Infectious Diseases 1994, 170: 173-179.
25. Vitt CR, Fidler JM, Ando D, Zimmerman RJ, Aukerman SL: Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. Journal of Infectious Diseases 1994, 169: 369-374.
26. Yamamoto Y, Klein TW, Friedman H, Kimura S, Yamaguchi H: Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunology and Medical Microbiology 1993, 7: 15-22.
27. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infection and Immunity 1993, 61: 4870-4877.
28. Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. Journal of Infectious Diseases 1991, 163: 579-583.
29. Vecchiarelli A, Monari C, Baldelli F, Pietrella D, Retini C, Tascini C, Francisci D, Bistoni F: Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. Journal of Infectious Diseases 1995, 171: 1448-1454.
30. Matsumoto M, Matsubara S, Matsuno T, Ono M, Yokota T: Protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) against various microbial infections in neutropenic mice. Microbiology and Immunology 1990, 34: 765-773.
31. Yamamoto Y, Uchida K, Klein TW, Friedman H, Yamaguchi H: Immunomodulators and fungal infections: use of antifungal drugs in combination with G-CSF. In: Friedman H (ed): Microbial infections. Plenum Press, New York, 1992, p. 231-241.